PTPA and acute myeloid leukemia: We show that a combination therapy using the CK2 inhibitor CX-4945, which retains SET in the nucleus, and FTY720, which disrupts the SET-PP2A binding in the cytoplasm, re-activates PP2A, reducing the viability of AML cells.